# Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

> **NCT04181762** · PHASE3 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 275 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** secukinumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04181762
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-07-07
- **Primary completion:** 2023-09-13
- **Final completion:** 2023-09-13
- **Target enrollment:** 275 (ACTUAL)
- **Why stopped:** Study terminated by sponsor due to futility analysis
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04181762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04181762, "Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04181762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*